Clinical Trial Update: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and immunogenicity of ALVAC-HIV with MF59 or AS01B adjuvants in healthy, HIV-uninfected adults; study completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ALVAC-HIV
• AS01B (AS01B)
• MF59

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-01-08